Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis
复制标题
DOI：
10.1212/01.wnl.0000125254.99397.68
复制
发表时间：
2004-05
期刊：
影响因子：
9.9
通讯作者：
Masaharu Takamori;Masakatsu Motomura;Naoki Kawaguchi;Y. Nemoto;Takamichi Hattori;Hiroaki Yoshikawa;K. Otsuka
中科院分区：
文献类型：
--
作者：
Masaharu Takamori;Masakatsu Motomura;Naoki Kawaguchi;Y. Nemoto;Takamichi Hattori;Hiroaki Yoshikawa;K. Otsuka
Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.
